Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Diagnosis and treatment of patients with pulmonary nontuberculous mycobacterial diseases in Arkhangelsk, Russia.

Eliseev P, Hinderaker SG, Heldal E, Tarasova I, Grjibovski A, Mariandyshev A.

Infect Genet Evol. 2019 Jun 1;73:358-361. doi: 10.1016/j.meegid.2019.05.022. [Epub ahead of print]

PMID:
31163274
2.

Building sustainable operational research capacity in Pakistan: starting with tuberculosis and expanding to other public health problems.

Fatima R, Yaqoob A, Qadeer E, Hinderaker SG, Heldal E, Zachariah R, Harries AD, Kumar AMV.

Glob Health Action. 2019;12(1):1555215. doi: 10.1080/16549716.2018.1555215.

3.

Outcome definitions for multidrug-resistant tuberculosis treated with shorter treatment regimens.

Schwoebel V, Chiang CY, Trébucq A, Piubello A, Aït-Khaled N, Koura KG, Heldal E, Van Deun A, Rieder HL.

Int J Tuberc Lung Dis. 2019 May 1;23(5):619-624. doi: 10.5588/ijtld.18.0798.

PMID:
31097072
4.

Local staff making sense of their tuberculosis data: key to quality care and ending tuberculosis.

Heldal E, Dlodlo RA, Mlilo N, Nyathi BB, Zishiri C, Ncube RT, Siziba N, Sandy C.

Int J Tuberc Lung Dis. 2019 May 1;23(5):612-618. doi: 10.5588/ijtld.18.0549.

PMID:
31097071
5.

Comprehensive care for all individuals with tuberculosis is needed now.

Dlodlo RA, Heldal E.

Lancet Glob Health. 2019 May;7(5):e536-e537. doi: 10.1016/S2214-109X(19)30150-0. Epub 2019 Mar 20. No abstract available.

6.

Challenges and opportunities to prevent tuberculosis in people living with HIV in low-income countries.

Harries AD, Schwoebel V, Monedero-Recuero I, Aung TK, Chadha S, Chiang CY, Conradie F, Dongo JP, Heldal E, Jensen P, Nyengele JPK, Koura KG, Kumar AMV, Lin Y, Mlilo N, Nakanwagi-Mukwaya A, Ncube RT, Nyinoburyo R, Oo NL, Patel LN, Piubello A, Rusen ID, Sanda T, Satyanarayana S, Syed I, Thu AS, Tonsing J, Trébucq A, Zamora V, Zishiri C, Hinderaker SG, Aït-Khaled N, Roggi A, Caminero Luna J, Graham SM, Dlodlo RA, Fujiwara PI.

Int J Tuberc Lung Dis. 2019 Feb 1;23(2):241-251. doi: 10.5588/ijtld.18.0207.

PMID:
30808459
7.

Immigrant screening for latent tuberculosis infection: numbers needed to test and treat, a Norwegian population-based cohort study.

Winje BA, Grøneng GM, White RA, Akre P, Aavitsland P, Heldal E.

BMJ Open. 2019 Jan 17;9(1):e023412. doi: 10.1136/bmjopen-2018-023412.

8.

Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area.

Rosales-Klintz S, Bruchfeld J, Haas W, Heldal E, Houben RMGJ, van Kessel F, Mandelbaum M, Matteelli A, Migliori GB, Oordt-Speets A, Solovic I, Vašáková M, Verver S, de Vlas SJ, Vonk Noordegraaf-Schouten MJM, de Vries G, Zenner D, van der Werf MJ.

Eur Respir J. 2019 Jan 17;53(1). pii: 1802077. doi: 10.1183/13993003.02077-2018. Print 2019 Jan. No abstract available.

PMID:
30655449
9.

Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.

Cornejo Garcia JG, Alarcón Guizado VA, Mendoza Ticona A, Alarcon E, Heldal E, Moore DAJ.

PLoS One. 2018 Dec 4;13(12):e0206658. doi: 10.1371/journal.pone.0206658. eCollection 2018.

10.

Rapid drug susceptibility testing and treatment outcomes for multidrug-resistant tuberculosis in Peru.

Obregón G, Zevallos K, Alarcón V, Puyén ZM, Chávez Inagaki O, Mendoza-Ticona A, Alarcón-Arrascue E, Heldal E, Moore DAJ.

Int J Tuberc Lung Dis. 2018 Nov 1;22(11):1350-1357. doi: 10.5588/ijtld.17.0894.

PMID:
30355416
11.

Tuberculosis in children treated with second-line drugs under programmatic conditions in Lima, Peru.

Villarreal J, Alarcón V, Alarcón-Arrascue E, Moore DAJ, Heldal E, Mendoza-Ticona A.

Int J Tuberc Lung Dis. 2018 Nov 1;22(11):1307-1313. doi: 10.5588/ijtld.17.0911.

PMID:
30355410
12.

Programmatic management of patients with pre-extensively drug-resistant tuberculosis in Peru, 2011-2014.

Alarcón V, Alarcón-Arrascue E, Mendoza-Ticona A, Obregón G, Cornejo J, Vargas D, De Los Ríos J, Moore DAJ, Heldal E.

Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1220-1226. doi: 10.5588/ijtld.17.0900.

PMID:
30236192
13.

A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis.

Heldal E.

Eur Respir J. 2017 Oct 12;50(4). pii: 1701696. doi: 10.1183/13993003.01696-2017. Print 2017 Oct. No abstract available.

14.

Infection control in hospitals managing drug-resistant tuberculosis in Pakistan: how are we doing?

Waheed Y, Khan MA, Fatima R, Yaqoob A, Mirza A, Qadeer E, Shakeel M, Heldal E, Kumar AMV.

Public Health Action. 2017 Mar 21;7(1):26-31. doi: 10.5588/pha.16.0125.

15.

Pre-treatment loss to follow-up among smear-positive TB patients in tertiary hospitals, Quetta, Pakistan.

Wali A, Kumar AMV, Hinderaker SG, Heldal E, Qadeer E, Fatima R, Ullah A, Safdar N, Yaqoob A, Anwar K, Ul Haq M.

Public Health Action. 2017 Mar 21;7(1):21-25. doi: 10.5588/pha.16.0118.

16.

Gastric specimens for diagnosing tuberculosis in adults unable to expectorate in Rawalpindi, Pakistan.

Aslam W, Tahseen S, Schomotzer C, Hussain A, Khanzada F, Ul Haq M, Mahmood N, Fatima R, Qadeer E, Heldal E.

Public Health Action. 2017 Jun 21;7(2):141-146. doi: 10.5588/pha.16.0126.

17.

Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.

Heldal E, Van Deun A, Chiang CY, Rieder HL.

Eur Respir J. 2017 Jun 1;49(6). pii: 1700228. doi: 10.1183/13993003.00228-2017. Print 2017 Jun. No abstract available.

18.

Health system factors influencing management of multidrug-resistant tuberculosis in four European Union countries - learning from country experiences.

de Vries G, Tsolova S, Anderson LF, Gebhard AC, Heldal E, Hollo V, Cejudo LS, Schmid D, Schreuder B, Varleva T, van der Werf MJ.

BMC Public Health. 2017 Apr 19;17(1):334. doi: 10.1186/s12889-017-4216-9.

19.

Contrasting trends of tuberculosis in the cities of San Pedro Sula and Tegucigalpa, Honduras, 2005-2014.

Varela-Martínez C, Yadon ZE, Marín D, Heldal E.

Rev Panam Salud Publica. 2016 Jan;39(1):51-59.

PMID:
27754537
20.

Implementation of the national tuberculosis guidelines on culture and drug sensitivity testing in Guatemala, 2013.

Samayoa-Peláez M, Ayala N, Yadon ZE, Heldal E.

Rev Panam Salud Publica. 2016 Jan;39(1):44-50.

PMID:
27754536
21.

Quality of tuberculosis care at different levels of health care in Brazil in 2013.

Bartholomay P, Pelissari DM, de Araujo WN, Yadon ZE, Heldal E.

Rev Panam Salud Publica. 2016 Jan;39(1):3-11.

PMID:
27754532
22.

Did FIDELIS projects contribute to the detection of new smear-positive pulmonary tuberculosis cases in China?

Lin Y, Chiang CY, Rusen ID, Hinderaker SG, Roldan A, Heldal E, Enarson DA, Zhang LX.

Public Health Action. 2016 Sep;6(3):176-180. Epub 2016 Sep 21.

23.

Multidrug-resistant tuberculosis in Norway: a nationwide study, 1995-2014.

Jensenius M, Winje BA, Blomberg B, Mengshoel AT, Lippe Bv, Hannula R, Bruun JN, Knudsen PK, Rønning JO, Heldal E, Dyrhol-Riise AM.

Int J Tuberc Lung Dis. 2016 Jun;20(6):786-92. doi: 10.5588/ijtld.15.0895.

PMID:
27155182
24.

BCG vaccination: a long-lasting protection against tuberculosis?--Authors' reply.

Nguipdop-Djomo P, Heldal E, Rodrigues LC, Abubakar I, Mangtani P.

Lancet Infect Dis. 2016 Apr;16(4):408-9. doi: 10.1016/S1473-3099(16)00134-1. No abstract available.

PMID:
27036342
25.

Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study.

Nguipdop-Djomo P, Heldal E, Rodrigues LC, Abubakar I, Mangtani P.

Lancet Infect Dis. 2016 Feb;16(2):219-26. doi: 10.1016/S1473-3099(15)00400-4. Epub 2015 Nov 19.

PMID:
26603173
26.

Intensified tuberculosis case finding among malnourished children in nutritional rehabilitation centres of Karnataka, India: missed opportunities.

Bhat PG, Kumar AM, Naik B, Satyanarayana S, Kg D, Nair SA, Md S, Heldal E, Enarson DA, Reid AJ.

PLoS One. 2013 Dec 16;8(12):e84255. doi: 10.1371/journal.pone.0084255. eCollection 2013.

27.

Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement.

Dara M, de Colombani P, Petrova-Benedict R, Centis R, Zellweger JP, Sandgren A, Heldal E, Sotgiu G, Jansen N, Bahtijarevic R, Migliori GB; Wolfheze Transborder Migration Task Force.

Eur Respir J. 2012 Nov;40(5):1081-90. doi: 10.1183/09031936.00053012. Epub 2012 May 31. Review.

28.

The FIDELIS initiative: innovative strategies for increased case finding.

Hinderaker SG, Rusen ID, Chiang CY, Yan L, Heldal E, Enarson DA.

Int J Tuberc Lung Dis. 2011 Jan;15(1):71-6.

PMID:
21276300
29.

Treatment of multidrug-resistant tuberculosis: definition of the outcome 'failure'.

Chiang CY, Van Deun A, Trébucq A, Heldal E, Caminero JA, Aït-Khaled N.

Int J Tuberc Lung Dis. 2011 Jan;15(1):4-5. No abstract available.

PMID:
21276289
30.

The role of entry screening in case finding of tuberculosis among asylum seekers in Norway.

Harstad I, Jacobsen GW, Heldal E, Winje BA, Vahedi S, Helvik AS, Steinshamn SL, Garåsen H.

BMC Public Health. 2010 Nov 4;10:670. doi: 10.1186/1471-2458-10-670.

31.

Predictive values of QuantiFERON-TB Gold testing in screening for tuberculosis disease in asylum seekers.

Harstad I, Winje BA, Heldal E, Oftung F, Jacobsen GW.

Int J Tuberc Lung Dis. 2010 Sep;14(9):1209-11.

PMID:
20819271
32.

Tuberculosis on the move.

Blumberg HM, Migliori GB, Ponomarenko O, Heldal E.

Lancet. 2010 Jun 19;375(9732):2127-9. doi: 10.1016/S0140-6736(10)60574-0. Epub 2010 May 18. No abstract available.

PMID:
20488513
33.

Drug supply shortages in 2010: the inexcusable failure of global tuberculosis control.

Rusen ID, Harries AD, Heldal E, Macé C.

Int J Tuberc Lung Dis. 2010 Mar;14(3):253-4. No abstract available.

PMID:
20132609
34.

Screening and treatment of latent tuberculosis in a cohort of asylum seekers in Norway.

Harstad I, Heldal E, Steinshamn SL, Garåsen H, Winje BA, Jacobsen GW.

Scand J Public Health. 2010 May;38(3):275-82. doi: 10.1177/1403494809353823. Epub 2009 Nov 13.

PMID:
19914972
35.

Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues.

Aït-Khaled N, Alarcon E, Bissell K, Boillot F, Caminero JA, Chiang CY, Clevenbergh P, Dlodlo R, Enarson DA, Enarson P, Ferroussier O, Fujiwara PI, Harries AD, Heldal E, Hinderaker SG, Kim SJ, Lienhardt C, Rieder HL, Rusen ID, Trébucq A, Van Deun A, Wilson N.

Int J Tuberc Lung Dis. 2009 Aug;13(8):927-35.

PMID:
19723371
36.

Tuberculosis screening and follow-up of asylum seekers in Norway: a cohort study.

Harstad I, Heldal E, Steinshamn SL, Garåsen H, Jacobsen GW.

BMC Public Health. 2009 May 14;9:141. doi: 10.1186/1471-2458-9-141.

37.

Evidence of protective effect of BCG vaccination in persons at low risk of tuberculosis in Nordic countries.

Brantsaeter AB, Romanus V, Andersen PH, Heldal E.

Int J Tuberc Lung Dis. 2009 Apr;13(4):440-5.

PMID:
19335948
38.

[Drug resistance in tuberculosis].

Winje BA, Mannsåker T, Langeland N, Heldal E.

Tidsskr Nor Laegeforen. 2008 Nov 20;128(22):2588-92. Review. Norwegian.

39.

School based screening for tuberculosis infection in Norway: comparison of positive tuberculin skin test with interferon-gamma release assay.

Winje BA, Oftung F, Korsvold GE, Mannsåker T, Ly IN, Harstad I, Dyrhol-Riise AM, Heldal E.

BMC Infect Dis. 2008 Oct 17;8:140. doi: 10.1186/1471-2334-8-140.

40.

Diagnosis and treatment of tuberculosis in undocumented migrants in low- or intermediate-incidence countries.

Heldal E, Kuyvenhoven JV, Wares F, Migliori GB, Ditiu L, Fernandez de la Hoz K, Garcia D.

Int J Tuberc Lung Dis. 2008 Aug;12(8):878-88.

PMID:
18647446
41.

Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda.

Cobelens FG, Heldal E, Kimerling ME, Mitnick CD, Podewils LJ, Ramachandran R, Rieder HL, Weyer K, Zignol M; Working Group on MDR-TB of the Stop TB Partnership.

PLoS Med. 2008 Jul 8;5(7):e150. doi: 10.1371/journal.pmed.0050150. No abstract available.

42.

Screening for tuberculosis infection among newly arrived asylum seekers: comparison of QuantiFERONTB Gold with tuberculin skin test.

Winje BA, Oftung F, Korsvold GE, Mannsåker T, Jeppesen AS, Harstad I, Heier BT, Heldal E.

BMC Infect Dis. 2008 May 14;8:65. doi: 10.1186/1471-2334-8-65.

43.

Revising the tuberculosis recording and reporting information system.

Norval PY, Heldal E, L'Herminez R, Laserson K, Godfrey A.

Int J Tuberc Lung Dis. 2008 Mar;12(3 Suppl 1):17-9.

PMID:
18302817
44.

The case of the Democratic Republic of Timor-Leste.

Heldal E, Araujo RM, Martins N, Sarmento J, Lopez C.

Bull World Health Organ. 2007 Aug;85(8):641-2. No abstract available.

45.

Impact of immigration on the molecular epidemiology of Mycobacterium tuberculosis in a low-incidence country.

Dahle UR, Eldholm V, Winje BA, Mannsåker T, Heldal E.

Am J Respir Crit Care Med. 2007 Nov 1;176(9):930-5. Epub 2007 Aug 2.

PMID:
17673698
46.

Cochrane systematic review of directly observed therapy for treating tuberculosis: good analysis of the wrong outcome.

Rusen ID, Aït-Khaled N, Alarcón E, Billo N, Bissell K, Boillot F, Caminero J, Chiang CY, Clevenbergh P, Dhliwayo P, Dlodlo R, Enarson DA, Ferroussier O, Fujiwara PI, Heldal E, Hinderaker SG, Kim SJ, Lienhardt C, Rieder HL, Trébucq A, Van Deun A, Wilson N.

Int J Tuberc Lung Dis. 2007 Feb;11(2):120-1. No abstract available.

PMID:
17263279
47.

Tuberculosis control in conflict-affected East Timor, 1996-2004.

Martins N, Heldal E, Sarmento J, Araujo RM, Rolandsen EB, Kelly PM.

Int J Tuberc Lung Dis. 2006 Sep;10(9):975-81.

PMID:
16964787
48.

Tuberculosis screening in migrants in selected European countries shows wide disparities.

Coker R, Bell A, Pitman R, Zellweger JP, Heldal E, Hayward A, Skulberg A, Bothamley G, Whitfield R, de Vries G, Watson JM.

Eur Respir J. 2006 Apr;27(4):801-7.

49.

Patient and health care system delays in the start of tuberculosis treatment in Norway.

Farah MG, Rygh JH, Steen TW, Selmer R, Heldal E, Bjune G.

BMC Infect Dis. 2006 Feb 24;6:33.

50.

Long-term risk of tuberculosis among immigrants in Norway.

Farah MG, Meyer HE, Selmer R, Heldal E, Bjune G.

Int J Epidemiol. 2005 Oct;34(5):1005-11. Epub 2005 Mar 31.

PMID:
15802379

Supplemental Content

Loading ...
Support Center